Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma Leukemia (2006) 20, 904-905.
Recent studies have highlighted the power of array-based comparative genomic hybridization (aCGH) to characterize chromosomal imbalances in mantle cell lymphoma (MCL). [1] [2] [3] Several of the deletions detected in these studies, including losses in 1p, 8p, 9q, 9p, 13q and 17p, have been shown to correlate with prognosis. 1, 2 It is widely assumed that chromosomal deletions exert their pathogenic effect through inactivation of tumor suppressor genes. However, novel reports have highlighted partial uniparental disomy (pUPD) as a frequent mechanism of tumor suppressor inactivation in acute leukemias and solid tumors. [4] [5] [6] By loss of (part of) one parental chromosome and gain of the homologue from the other parent, pUPD results in loss of heterozygosity (LOH) without chromosomal deletion. As the gene dosage is not altered, pUPD cannot be detected by conventional cytogenetics, fluorescence in situ hybridization or aCGH. To investigate the role of this mechanism in MCL, we have performed genome-wide analyses of single nucleotide polymorphisms (SNPs) using a 100K SNP-array Examples of partial uniparental disomy (pUPD) detected in mantle cell lymphoma cell lines. The profile of genomic imbalances is given as a black line with a value of 2 indicating a balanced status. The -log 10 of P-values for loss of heterozygosity (LOH) are overlaid in gray, and those exceeding 15 were considered indicative of LOH (for a better display, larger values were cut at 20). Chromosomes are shown from pter (left) to qter (right). Regions meeting the defined criteria for pUPD are underlaid by black bars.
Letters to the Editor been extensively studied by aCGH. 2, 7 Copy number and LOH analyses were performed using the Chromosome Copy Number Analysis Tool (version 2.0.0.9, Affymetrix) applying a 0.5 Mb genome smoothing filter.
Partial UPD was defined as a region spanning at least 50 SNPs with homozygous allele calls and a -log 10 (P-value) for LOH above 15 in the absence of a deletion.
A median number of 8 (range ¼ 5-20) pUPDs were identified in the samples, indicating that pUPD is a common phenomenon in MCL cell lines. Most interestingly, the regions of pUPD detected in the MCL cell lines affected regions of recurrent chromosomal deletion described in the aCGH studies (Figure 1 ).
1-3 Furthermore, we found an excellent agreement between copy number changes detected by aCGH and SNParray analyses.
To study whether pUPD is common also in other types of lymphomas, we took advantage of the 10K SNP-array data publicly available from the Wellcome Trust Sanger Institute Cancer Genome Project (http://www.sanger.ac.uk/genetics/ CGP). We focused on Burkitt lymphoma (BL) cell lines because this lymphoma shows a low number of chromosomal changes in addition to the pathogenetic Burkitt translocation t(8;14) (q24;q32) or its variants. Among others, we observed recurrent pUPD in 17p and 18q in BL cell lines. Chromosome 17p contains the TP53 tumor suppressor gene, whereas 18q harbors the candidate tumor suppressor NOXA, which is homozygously deleted in a BL cell line (Mestre et al., submitted).
In summary, these findings show pUPD to be recurrent in lymphoma and to affect regions commonly targeted by deletions. Further studies in primary tumor samples are mandatory to extend these findings, but problems of allele discrimination caused by contaminating non-neoplastic cells have to be resolved. If associating genetic findings with clinical outcome, pUPD has to be considered as a mechanism of tumor suppressor gene inactivation alternative to chromosomal deletion. The routine use of frontline all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy has greatly improved the outcome of APL, particularly by reducing the incidence of relapses, notably early relapses. Overall, the combination of ATRA and anthracycline-based chemotherapy yields complete remission rates greater than 90% in newly diagnosed APL. 1, 2 With maintenance combining continuous 6-mercaptopurine (6MP) and methotrexate (MTX) to intermittent ATRA and possibly with early introduction of chemotherapy during induction treatment, the relapse risk in APL has now been reduced to 10-15%. [1] [2] [3] [4] Before the ATRA era, the large majority of first relapses in APL occurred within 3 years of CR achievement, and only 2-3% of the patients relapsed after 4 years. 5, 6 Theoretically, the possibility exists that the addition of ATRA to chemotherapy in newly diagnosed APL may only delay some of the relapses that were seen earlier with chemotherapy alone. The incidence and characteristics of late relapses occurring after ATRA-and anthracycline-based chemotherapy, however, are not known.
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Between 1991 and 1997 (APL 91 and 93 trials) 630 newly diagnosed APL patients received ATRA combined to or followed by daunorubicin-cytarabine chemotherapy (for a total of three courses), with or without (randomization) maintenance treatment by 6MP and methotrexate and/or intermittent ATRA. 1, 7 A total of 582 (92.5%) patients achieved hematological CR and 154 (26.4%) relapsed, after 5-120 months. Nineteen of those
